Tags

Type your tag names separated by a space and hit enter

[Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa].
Arch Invest Med (Mex). 1977; 8(2):123-8.AI

Abstract

It is widely known that administration of L-Dopa benefits patients with Parkinson's syndrome and combination of this drug with decarboxilase does it to a greater extent. In the present study 20 patients with Parkinson's syndrome received MK 486, a combination of L-Dopa and Carbidopa 10:1 (250 mg of the fomer and 25 mg of the latter). The aim of this study was to evaluate therapeutic activity of this drug combination. It was found that MK 486 is effective for controlling clinical manifestation in Parkinson's syndrome. Although side effects were seen frequently, they diminished or disappeared after time of drug administration.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

spa

PubMed ID

907417

Citation

Lombardo, L, and R De la Garza. "[Treatment of Parkinson's Syndrome With a Combination of Levodopa and Carbidopa]." Archivos De Investigacion Medica, vol. 8, no. 2, 1977, pp. 123-8.
Lombardo L, De la Garza R. [Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa]. Arch Invest Med (Mex). 1977;8(2):123-8.
Lombardo, L., & De la Garza, R. (1977). [Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa]. Archivos De Investigacion Medica, 8(2), 123-8.
Lombardo L, De la Garza R. [Treatment of Parkinson's Syndrome With a Combination of Levodopa and Carbidopa]. Arch Invest Med (Mex). 1977;8(2):123-8. PubMed PMID: 907417.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa]. AU - Lombardo,L, AU - De la Garza,R, PY - 1977/1/1/pubmed PY - 1977/1/1/medline PY - 1977/1/1/entrez SP - 123 EP - 8 JF - Archivos de investigacion medica JO - Arch Invest Med (Mex) VL - 8 IS - 2 N2 - It is widely known that administration of L-Dopa benefits patients with Parkinson's syndrome and combination of this drug with decarboxilase does it to a greater extent. In the present study 20 patients with Parkinson's syndrome received MK 486, a combination of L-Dopa and Carbidopa 10:1 (250 mg of the fomer and 25 mg of the latter). The aim of this study was to evaluate therapeutic activity of this drug combination. It was found that MK 486 is effective for controlling clinical manifestation in Parkinson's syndrome. Although side effects were seen frequently, they diminished or disappeared after time of drug administration. SN - 0066-6769 UR - https://www.unboundmedicine.com/medline/citation/907417/[Treatment_of_Parkinson's_syndrome_with_a_combination_of_levodopa_and_carbidopa]_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.